Deferiprone

Annals of the New York Academy of Sciences

Volumn 1202, Issue , 2010, Pages 75-78

  Piga, Antonio ^a   Roggero, Simona ^a   Salussolia, Ilaria ^a   Massano, Davide ^a   Serra, Melania ^a   Longo, Filomena ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

chelation; deferiprone; iron; thalassemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; GLUCURONOSYLTRANSFERASE 1A6; LIVER ENZYME;

ABDOMINAL PAIN; AGRANULOCYTOSIS; ARTHROPATHY; BLOOD CELL COUNT; CARDIAC IRON LOAD; CARDIOTOXICITY; CLINICAL EVALUATION; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENETIC VARIABILITY; HEART DISEASE; HEART PROTECTION; HUMAN; IRON CHELATION; IRON OVERLOAD; IRON URINE LEVEL; LIVER FIBROSIS; LIVER IRON CONCENTRATION; MORTALITY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; SIDE EFFECT; THALASSEMIA; TOXIC HEPATITIS; VOMITING;

EID: 77955864146     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05586.x     Document Type: Conference Paper

References (29)

1. Kontoghiorghes, G.J. et al. 1987. 1,2-Dimethyl-3- hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Lancet 1: 1294-1295.
2. Boddaert, N. et al. 2007. Selective ironchelation in Friedreich ataxia: biologic and clinical implications. Blood 110: 401-408.
3. Sohn, Y.S. et al. 2008. Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood 111: 1690-1699.
4. Matsui, D. et al. 1991. Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia. Clin. Pharmacol. Ther. 50: 294-298.
5. Olivieri, N.F. et al. 1998. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.N. Engl. J. Med. 339: 417-423.
6. Callea, F. 1998. Iron chelation with oral deferiprone in patients with thalassemia. N. Engl. J. Med. 339: 1710-1711.
7. Wanless, I.R. et al. 2002. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 100: 1566-1569.
8. Ceci, A. et al. 2002. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br. J. Haematol. 118: 330-336.
9. Al-Refaie, F.N., B. Wonke & A.V. Hoffbrand. 1994. Deferiprone-associated myelotoxicity. Eur. J. Haematol. 53: 298-301.
10. Al-Refaie, F.N. et al. 1995. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. Br. J. Haematol. 91: 224-229.
11. Cohen, A.R. et al. 2003. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 102: 1583-1587.
12. Naithani, R., J. Chandra & S. Sharma. 2005. Safety of oral iron chelator deferiprone in young thalassaemics. Eur. J. Haematol. 74: 217-220.
13. Vlachaki, E. et al. 2008. Deferiprone-related arthropathy of the knee in a thalassemic patient: report of a case and review of the literature. Clin. Rheumatol. 27: 1459-1461.
14. Kellenberger, C.J. et al. 2004. Radiographic andMRIfeatures of deferiprone-related arthropathy of the knees in patients with beta-thalassemia. Am. J. Roentgenol. 183: 989-994.
15. Hershko, C.M. et al. 2005. Iron chelation therapy. Curr. Hematol. Rep. 4: 110-116.
16. Berkovitch M. et al. 1994. Arthropathy in thalassaemia patients receiving deferiprone. Lancet 343: 1471-1472.
17. Benoit-Biancamano, M.O. et al. 2009. Deferiprone glucuronidation by human tissues and recombinant UDP glucuronosyltransferase 1A6: an in vitro investigation of genetic and splice variants. Drug. Metab. Dispos. 37: 322-329.
18. Piga,A. et al. 2005. Deferiprone: new insight.Ann. N.Y.Acad. Sci. 1054: 169-174.
19. Fischer R. et al. 2003.Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br. J. Haematol. 121: 938-948.
20. Roberts, D.J. et al. 2007. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst. Rev. 3: CD004839.
21. Anderson, L.J. et al. 2001. CardiovascularT2-star (T2-)magnetic resonance for the early diagnosis of myocardial iron overload. Eur. Heart J. 22: 2171-2179.
22. Anderson, L.J. et al. 2002. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine onmyocardial iron concentrations and ventricular function in betathalassaemia. Lancet 360: 516-520.
23. Piga, A. et al. 2003. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patientswith thalassemia major: a retrospective analysis. Haematologica 88: 489-496.
24. Borgna-Pignatti C. et al. 2006. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 107: 3733-3737.
25. Peng, C.T. et al. 2006. Deferiprone or deferoxamine vs. combination therapy in patients with beta-thalassemia major: a case study in Taiwan. Hemoglobin 30: 125-130.
26. Pennell, D.J. et al. 2006. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 107: 3738-3744.
27. Maggio, A. et al. 2009. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol. Dis. 42: 247-251.
28. Tanner, M.A. et al. 2007. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 115: 1876-1884.
29. Hershko, C. et al. 2004. Purging iron from the heart. Br. J. Haematol. 125: 545-551.